Patents Assigned to Shionogi & Co., Ltd.
-
Publication number: 20230210822Abstract: Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration. A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I): wherein R1 is haloalkyl or non-aromatic carbocyclyl, R2 is a hydrogen atom or halogen, R3 is halogen, ring A is a group represented by the formula: -L1- is —O—(CH2)—, —(CH2)2—, or the like, R4 is alkyl or haloalkyl, and R5 is alkylcarbonyl or carbamoyl, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 20, 2021Publication date: July 6, 2023Applicant: Shionogi & Co., Ltd.Inventors: Hideo YUKIOKA, Atsuyuki SHIMAZAKI, Tadateru HAMADA, Naoki OHYABU
-
Patent number: 11685740Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.Type: GrantFiled: June 16, 2021Date of Patent: June 27, 2023Assignee: Shionogi & Co., Ltd.Inventors: Koji Masuda, Shuichi Sugiyama, Toru Yamada, Eiichi Kojima, Tomoyuki Ogawa, Naotake Kobayashi, Hiroyuki Kai
-
Publication number: 20230190174Abstract: The signal processing apparatus receives an input acoustic signal, and amplitude-modulates the received input acoustic signal to generate an output acoustic signal having an amplitude change corresponding to a frequency of a gamma wave, and outputs the generated output acoustic signal.Type: ApplicationFiled: February 21, 2023Publication date: June 22, 2023Applicants: Pixie Dust Technologies, Inc., Shionogi & Co., Ltd.Inventors: Yoshiki NAGATANI, Kazuki TAKAZAWA, Koichi OGAWA, Kazuma MAEDA, Tatsuya YANAGAWA
-
Publication number: 20230190173Abstract: A signal processing apparatus receives an input acoustic signal, acquires a first acoustic signal having a periodic variation corresponding to the frequency of gamma waves, and outputs an output acoustic signal based on the acquired first acoustic signal and the second acoustic signal. The second acoustic signal is based on the input acoustic signal.Type: ApplicationFiled: February 16, 2023Publication date: June 22, 2023Applicants: Pixie Dust Technologies, Inc., Shionogi & Co., Ltd.Inventors: Yoshiki NAGATANI, Kazuki TAKAZAWA, Koichi OGAWA, Kazuma MAEDA
-
Publication number: 20230183205Abstract: By wet-pulverizing a compound represented by Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (hereinafter referred to as a compound represented by Formula (I) or the like), it is possible to provide a crystal of the compound represented by Formula (I) or the like and a pharmaceutical composition containing the same having excellent stability. In addition, by wet-kneading and/or wet-granulating the compound represented by Formula (I) or the like, it is possible to provide a pharmaceutical composition containing the compound represented by Formula (I) or the like having excellent stability.Type: ApplicationFiled: May 13, 2021Publication date: June 15, 2023Applicant: Shionogi & Co., Ltd.Inventors: Yuya OCHII, Chika NISHIDA, Go KIMURA, Shinichi ODA, Shohei MAJIMA, Takahiro OSHIMA
-
Publication number: 20230173027Abstract: A pharmaceutical composition containing the substance according to any one of the following (a) to (c), an organic acid, a metal salt of an organic acid, and a sugar and/or a sugar alcohol, wherein when the pharmaceutical composition is dissolved in distilled water for injection, a pH of the pharmaceutical composition is 3.0 to 4.Type: ApplicationFiled: April 19, 2021Publication date: June 8, 2023Applicants: Shionogi & Co., Ltd., StemRim Inc.Inventors: Nao MATSUOKA, Shuichi HATANO, Yuya KUGA, Maki OKABE, Takehiko YAMAZAKI, Koichi YOKOTA
-
Publication number: 20230158036Abstract: The present invention relates to a pharmaceutical composition comprising a P2X3 and/or P2X2/3 receptor antagonist for the treatment of neuropathic pain, nociceptive pain or visceral pain, as well as interstitial cystitis and/or bladder pain syndrome. It is a pharmaceutical composition for treating and/or preventing neuropathic pain, nociceptive pain, or visceral pain, as well as interstitial cystitis and/or bladder pain syndrome, comprising a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 2, 2021Publication date: May 25, 2023Applicant: Shionogi & Co., Ltd.Inventors: Takayuki KAMEYAMA, Hiroyuki KAI
-
Patent number: 11649236Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.Type: GrantFiled: May 30, 2019Date of Patent: May 16, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Yoshiyuki Taoda, Yuto Unoh
-
Publication number: 20230143664Abstract: Provided are compounds having a serotonin 5-HT2A receptor inverse agonism, pharmaceutically acceptable salts thereof, and a composition comprising them, A composition comprising the compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or 2; R4 is substituted or unsubstituted non-aromatic nitrogen-containing heterocyclyl or the like; L is —NR8— or the like; R8 is a hydrogen atom or the like; R8 is each independently a hydrogen atom or the like; R8 is each independently a hydrogen atom or the like; p is 1 or 2; and R7 is a group represented by Formula: wherein R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; R11 is halogen or the like; and m is 0 or 1.Type: ApplicationFiled: March 25, 2021Publication date: May 11, 2023Applicant: Shionogi & Co., Ltd.Inventors: Kenji NAKAHARA, Kouki FUCHINO, Kotaro NAGATANI
-
Patent number: 11643458Abstract: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.Type: GrantFiled: May 30, 2019Date of Patent: May 9, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Tatsuya Takahashi, Mai Yoshikawa, Sosuke Yoneda, Junji Onoda, Etsuo Nakamura, Tsuguo Miyauchi, Toshiyuki Asaki, Erika Kasai
-
Patent number: 11638717Abstract: The purpose of the present invention is to provide novel complexes that improve the effect of nucleic acid medicines. Provided is a complex in which a multibranched lipid(s) binds through a linker to a strand of an oligonucleotide comprising a nucleic acid medicine having suppressing activity of the target gene expression.Type: GrantFiled: March 28, 2018Date of Patent: May 2, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Akira Kugimiya, Mitsuaki Sekiguchi, Norikazu Kuroda, Jun Nakamura, Tetsuya Tanino, Yasunori Mitsuoka, Takeshi Kasuya, Yasuharu Kato
-
Publication number: 20230128162Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula (I): wherein Y is N or the like; R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is substituted or unsubstituted aromatic carbocyclyl or the like; R3 is substituted or unsubstituted aromatic heterocyclyl or the like; —X— is —NH— or the like; m is 1 or the like; R5a is each independently a hydrogen atom or the like; R5b is each independently a hydrogen atom or the like; n is 1 or the like; R4a is each independently a hydrogen atom or the like; and R4b is each independently a hydrogen atom or the like, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 17, 2022Publication date: April 27, 2023Applicants: Shionogi & Co., Ltd., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Yuki TACHIBANA, Shota UEHARA, Yuto UNOH, Kenji NAKAHARA, Yoshiyuki TAODA, Koji KASAMATSU, Yukiko YAMATSU, Shigeru ANDO, Atsuhiro IIMURO, Takahiro SUTO, Michihito SASAKI
-
Publication number: 20230117695Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound. An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 30, 2022Publication date: April 20, 2023Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Shionogi & Co., Ltd.Inventors: Akihiro ISHII, Akihiko SATO, Makoto KAWAI, Yoshiyuki TAODA
-
Patent number: 11629154Abstract: The present invention provides a compound which has an effect of inhibiting amyloid ßproduction, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid ßproteins. A compound of Formula (I) wherein R3 is each independently alkyl optionally substituted with halogen, cyano, alkyloxy, haloalkyloxy or non-aromatic carbocyclyl, or the like; t is integer from 0 to 3; R5 is a hydrogen atom or halogen; R6 is selected from the group consisting of a hydrogen atom, halogen, and substituted or unsubstituted alkyl; ring B is a substituted or unsubstituted pyrazine or the like; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 25, 2019Date of Patent: April 18, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Genta Tadano, Shinji Suzuki, Ken-ichi Kusakabe
-
Publication number: 20230059640Abstract: A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)— or the like: each R1 independently represents a halogen atom or the like: each of R2a and R2b independently represents a hydrogen atom or the like: R3 represents an alkyl group or a haloalky 1 group: R4 represents a hydrogen atom or an alkyl group: and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof, and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 27, 2020Publication date: February 23, 2023Applicant: Shionogi & Co., Ltd.Inventors: Tomokazu YOSHINAGA, Yutaka TOMIDA
-
Publication number: 20230058677Abstract: The present invention provides a compound represented by the following Formula (I): wherein ring A is a C5-C7 non-aromatic carbocycle or a 5- to 7-membered non-aromatic heterocycle; ring B is a benzene ring or the like; Q is —NHC(O)— or a 5-membered aromatic heterocycle; R1 is each independently halogen or the like; R2a and R2b are each independently hydrogen, alkyl, or haloalkyl; R3 is alkyl or the like; R4 and R5 are each independently hydrogen or the like; R6 is each independently halogen, alkyl, haloalkyl, alkyloxy, haloalkyloxy, or alkyloxyalkyl; n is an integer of 1 to 3; and m is an integer of 0 to 3.Type: ApplicationFiled: November 27, 2020Publication date: February 23, 2023Applicant: Shionogi & Co., Ltd.Inventors: Yutaka TOMIDA, Takashi KAWASUJI
-
Patent number: 11578084Abstract: Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)?: wherein A is S or O; R1a is substituted or unsubstituted alkyloxy or the like, R2a to R2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R3 is each independently halogen or the like, r is an integer of 0 to 4, R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 25, 2019Date of Patent: February 14, 2023Assignee: Shionogi & Co., Ltd.Inventors: Hiroyuki Tobinaga, Koji Masuda
-
Publication number: 20230040262Abstract: The present invention provides industrially suitable processes for preparing intermediates in the production of substituted polycyclic pyridone derivatives having a cap-dependent endonuclease inhibitory activity.Type: ApplicationFiled: February 24, 2022Publication date: February 9, 2023Applicant: Shionogi & Co., Ltd.Inventors: Kazuya OKAMOTO, Tatsuhiko UENO, Yoshio HATO, Toshikazu HAKOGI, Shohei MAJIMA
-
Patent number: 11561230Abstract: A reference standard set for BNP measurement, including a plurality of reference standards including BNP-32 and proBNP, wherein the ratio BNP-32/proBNP (mole ratio) differs between the reference standards, and when a reference standard having a high mole ratio and a reference standard having a low mole ratio are compared, the BNP concentration, which is the sum total of the BNP-32 concentration and the proBNP concentration, is lower in the reference standard having a high mole ratio than in the reference standard having a low mole ratio.Type: GrantFiled: December 28, 2018Date of Patent: January 24, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Norio Ota, Keiichi Masuta
-
Publication number: 20220396561Abstract: A crystal of a 1,3,5-triazine derivative or a solvate thereof, and a method for producing the same are provided. The present invention relates to a crystal of a compound represented by Formula (I) or a solvate thereof: and relates to a pharmaceutical composition containing the same. The present invention also relates to a crystal of a compound represented by Formula (I), or a solvate thereof.Type: ApplicationFiled: September 18, 2020Publication date: December 15, 2022Applicant: Shionogi & Co., Ltd.Inventors: Hiroyuki KAI, Toshikatsu MAKI, Shinichi ODA, Kazunori BAN, Koichi TSUBONE, Masahiro HOSOYA, Yuki MURAKAMI